Status:
COMPLETED
Observational Non-Interventional Study With Spiriva Respimat in COPD Patients
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
18+ years
Brief Summary
This observational non-interventional study is designed to demonstrate the improvement of physical function in COPD patients on treatment with Spiriva Respimat and allows adverse events to be recorded...
Eligibility Criteria
Inclusion
- COPD patients who require treatment with longacting anticholinergic
Exclusion
- Patients cannot be recruited if any of the general or specific contraindications listed in the Patient information leaflet or the Summary of Product Characteristics applies. Spiriva® Respimat® is contraindicated in patients with hypersensitivity to tiotropium bromide, atropine or its derivatives, e.g. ipratropium or oxitropium or to any of the excipients.
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
1280 Patients enrolled
Trial Details
Trial ID
NCT00699699
Start Date
June 1 2008
Last Update
April 10 2014
Active Locations (188)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site
Aachen, Germany
2
Boehringer Ingelheim Investigational Site
Amberg, Germany
3
Boehringer Ingelheim Investigational Site
Auerbach, Germany
4
Boehringer Ingelheim Investigational Site 1
Augsburg, Germany